4Moving Biotech Completes Enrollment in Phase 2a INFLAM MOTION Study Evaluating First-in-class Intra-articular GLP-1 Therapy Targeting Synovitis as a Driver of Pain and Disease Progression in Knee Osteoarthritis
Kort samengevat
INFLAM MOTION enrolled 129 patients with knee osteoarthritis associated with synovitis across Europe, the United States and Canada, targeting an inflammatory phenotype associated with structural progression
Verder lezen bij de bron
Bekijk het volledige nieuwsbericht rechtstreeks bij FinanzNachrichten.de.
Lees het volledige bericht ↗